velmanase alfa: clinical use

Prescribing considerations

• Treatment should be supervised by a clinician experienced in alpha-mannosidosis or lysosomal enzyme replacement therapy.
• Ensure immediate access to management of hypersensitivity, anaphylaxis and other infusion-related reactions.
• Consider home infusion only after satisfactory tolerance, individual assessment and patient or caregiver training.
• Periodically evaluate clinical benefit; consider discontinuation if no clear benefit is observed.

Contraindications and cautions

• Severe allergic reaction to velmanase alfa or any formulation excipient.
• Use caution after infusion-related or hypersensitivity reactions; management may require interruption, slower administration or supportive treatment.
• Established neurological, cognitive and irreversible skeletal complications are not expected to respond because the enzyme does not cross the blood–brain barrier.

Monitoring

• Record product name and batch number for biological traceability.
• Observe for infusion-related reactions during administration and afterwards according to clinical circumstances.
• Assess ongoing clinical benefit and deterioration.
• Test for anti-velmanase alfa antibodies after severe infusion reactions or loss of treatment effect.

Clinical pharmacology

Velmanase alfa is recombinant human lysosomal alpha-mannosidase. It is taken up by cells through mannose receptors and degrades mannose-rich oligosaccharides within lysosomes.

Formulation and product differences

• White to off-white powder requiring aseptic reconstitution for intravenous infusion.
• The reconstituted solution should be clear; do not use if discoloured or containing opaque particles.
• Administration requires a pump and low protein-binding in-line filter. It must not be mixed with other medicines.

Solution for infusion

Route: Intravenous

Strengths: 10 mg